메뉴 건너뛰기




Volumn 60, Issue 1, 2014, Pages 15-18

Sorafenib use in hepatocellular carcinoma: More questions than answers

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CATECHOLAMINE; ENDOTHELIN 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; NITROUS OXIDE; PLACEBO; RENIN; SORAFENIB; UROTENSIN II; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

EID: 84894364863     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27044     Document Type: Article
Times cited : (29)

References (25)
  • 1
    • 82455162643 scopus 로고    scopus 로고
    • Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy
    • Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, et al., SOFIA (SOraFenib Italian Assessment) study group Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011;54:2055-2063.
    • (2011) Hepatology , vol.54 , pp. 2055-2063
    • Iavarone, M.1    Cabibbo, G.2    Piscaglia, F.3    Zavaglia, C.4    Grieco, A.5    Villa, E.6
  • 4
    • 84870528219 scopus 로고    scopus 로고
    • Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib
    • Spirli C, Morell CM, Locatelli L, Okolicsanyi S, Ferrero C, Kim AK, et al. Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib. Hepatology 2012;56:2363-2374.
    • (2012) Hepatology , vol.56 , pp. 2363-2374
    • Spirli, C.1    Morell, C.M.2    Locatelli, L.3    Okolicsanyi, S.4    Ferrero, C.5    Kim, A.K.6
  • 5
    • 20044382799 scopus 로고    scopus 로고
    • Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
    • Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-972.
    • (2005) J Clin Oncol , vol.23 , pp. 965-972
    • Strumberg, D.1    Richly, H.2    Hilger, R.A.3    Schleucher, N.4    Korfee, S.5    Tewes, M.6
  • 6
    • 84864997618 scopus 로고    scopus 로고
    • A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma
    • Amato R, Zhai J, Willis J, Saxena S, DeFoe M. A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2012;10:153-158.
    • (2012) Clin Genitourin Cancer , vol.10 , pp. 153-158
    • Amato, R.1    Zhai, J.2    Willis, J.3    Saxena, S.4    DeFoe, M.5
  • 7
    • 84555208775 scopus 로고    scopus 로고
    • Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment
    • Mancuso A, Di Paola ED, Leone A, Catalano A, Calabrò F, Cerbone L, et al. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment. BJU Int 2012;109:200-206.
    • (2012) BJU Int , vol.109 , pp. 200-206
    • Mancuso, A.1    Di Paola, E.D.2    Leone, A.3    Catalano, A.4    Calabrò, F.5    Cerbone, L.6
  • 8
    • 84862737988 scopus 로고    scopus 로고
    • First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study
    • Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, et al. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. Int J Clin Pract 2012;66:675-683.
    • (2012) Int J Clin Pract , vol.66 , pp. 675-683
    • Lencioni, R.1    Kudo, M.2    Ye, S.L.3    Bronowicki, J.P.4    Chen, X.P.5    Dagher, L.6
  • 9
    • 80053041858 scopus 로고    scopus 로고
    • Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis
    • Abou-Alfa GK, Amadori D, Santoro A, Figer A, De Greve J, Lathia C, et al. Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis. Gastrointest Cancer Res 2011;4:40-44.
    • (2011) Gastrointest Cancer Res , vol.4 , pp. 40-44
    • Abou-Alfa, G.K.1    Amadori, D.2    Santoro, A.3    Figer, A.4    De Greve, J.5    Lathia, C.6
  • 10
    • 64649083367 scopus 로고    scopus 로고
    • Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301
    • Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009;27:1800-1805.
    • (2009) J Clin Oncol , vol.27 , pp. 1800-1805
    • Miller, A.A.1    Murry, D.J.2    Owzar, K.3    Hollis, D.R.4    Kennedy, E.B.5    Abou-Alfa, G.6
  • 11
    • 84890274647 scopus 로고    scopus 로고
    • Brivanib (BRI) versus sorafenib (SOR) as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma (HCC): results from the randomized phase 3 BRISK-FL study
    • Johnson P, Qin S, Park J-W. Brivanib (BRI) versus sorafenib (SOR) as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma (HCC): results from the randomized phase 3 BRISK-FL study. J Clin Oncol 2013;31:3517-3524.
    • (2013) J Clin Oncol , vol.31 , pp. 3517-3524
    • Johnson, P.1    Qin, S.2    Park, J.-W.3
  • 12
    • 84885587718 scopus 로고    scopus 로고
    • Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study
    • Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013;31:3509-3516.
    • (2013) J Clin Oncol , vol.31 , pp. 3509-3516
    • Llovet, J.M.1    Decaens, T.2    Raoul, J.L.3    Boucher, E.4    Kudo, M.5    Chang, C.6
  • 13
    • 60549118166 scopus 로고    scopus 로고
    • Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
    • Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009;20:227-230.
    • (2009) Ann Oncol , vol.20 , pp. 227-230
    • Scartozzi, M.1    Galizia, E.2    Chiorrini, S.3    Giampieri, R.4    Berardi, R.5    Pierantoni, C.6
  • 14
    • 84890287907 scopus 로고    scopus 로고
    • A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer
    • Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, et al. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res 2013;19:6614-6623.
    • (2013) Clin Cancer Res , vol.19 , pp. 6614-6623
    • Zhu, A.X.1    Finn, R.S.2    Mulcahy, M.3    Gurtler, J.4    Sun, W.5    Schwartz, J.D.6
  • 15
    • 80054710749 scopus 로고    scopus 로고
    • Pharmacodynamic (PD) assessment of blood pressure (BP) in a randomized dose-ranging trial of sorafenib (S)
    • abstr 3016).
    • Maitland ML, Karrison T, Bakris GL, Fox K, Janisch LA, Karovic S, et al. Pharmacodynamic (PD) assessment of blood pressure (BP) in a randomized dose-ranging trial of sorafenib (S). J Clin Oncol 2011;29:(suppl; abstr 3016).
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL
    • Maitland, M.L.1    Karrison, T.2    Bakris, G.L.3    Fox, K.4    Janisch, L.A.5    Karovic, S.6
  • 17
    • 47949089077 scopus 로고    scopus 로고
    • VEGF-targeted therapy: mechanisms of anti-tumour activity
    • Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008;8:579-591.
    • (2008) Nat Rev Cancer , vol.8 , pp. 579-591
    • Ellis, L.M.1    Hicklin, D.J.2
  • 18
    • 75649116842 scopus 로고    scopus 로고
    • Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib
    • Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010;15:85-92.
    • (2010) Oncologist , vol.15 , pp. 85-92
    • Vincenzi, B.1    Santini, D.2    Russo, A.3    Addeo, R.4    Giuliani, F.5    Montella, L.6
  • 19
    • 84872771082 scopus 로고    scopus 로고
    • Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma
    • Lee JH, Chung YH, Kim JA, Shim JH, Lee D, Lee HC, et al. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer 2013;119:136-142.
    • (2013) Cancer , vol.119 , pp. 136-142
    • Lee, J.H.1    Chung, Y.H.2    Kim, J.A.3    Shim, J.H.4    Lee, D.5    Lee, H.C.6
  • 20
    • 77349102071 scopus 로고    scopus 로고
    • Modified RECIST (mRECIST) assessment for hepatocellular carcinoma
    • Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
    • (2010) Semin Liver Dis , vol.30 , pp. 52-60
    • Lencioni, R.1    Llovet, J.M.2
  • 21
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3    Wanders, J.4    Kaplan, R.S.5    Rubinstein, L.6
  • 22
    • 83855160927 scopus 로고    scopus 로고
    • Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
    • Edeline J, Boucher E, Rolland Y, Vauleon E, Pracht M, Perrin C, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012;118:147-156.
    • (2012) Cancer , vol.118 , pp. 147-156
    • Edeline, J.1    Boucher, E.2    Rolland, Y.3    Vauleon, E.4    Pracht, M.5    Perrin, C.6
  • 23
    • 84857008164 scopus 로고    scopus 로고
    • Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma
    • Finn RS, Kang YK, Mulcahy M, Polite BN, Lim HY, Walters I, et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012;18:2090-2098.
    • (2012) Clin Cancer Res , vol.18 , pp. 2090-2098
    • Finn, R.S.1    Kang, Y.K.2    Mulcahy, M.3    Polite, B.N.4    Lim, H.Y.5    Walters, I.6
  • 24
    • 84885587718 scopus 로고    scopus 로고
    • Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study
    • Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013;31:3509-3516.
    • (2013) J Clin Oncol , vol.31 , pp. 3509-3516
    • Llovet, J.M.1    Decaens, T.2    Raoul, J.L.3    Boucher, E.4    Kudo, M.5    Chang, C.6
  • 25


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.